George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
YAWN. @mke33
New video presentation by Berry Beumer - president - Advanced Imaging Kromek
Watch "CZT in CT and SPECT Imaging" on YouTube
Very clear and informative and shows where Kmk's tech is taking the future of medical imaging.
https://youtu.be/Nny0iJwX5s4?si=h2xIE68UVnuB6GCm
DYOR
Good to do more research as Ironknut mentioned and develop understanding and confidence.
I found this (although old) useful
https://www.equitydevelopment.co.uk/hubfs/Research/Kromek/Kromek%20Group%20%20%20final%20note%20%20%2014th%20July%202021.pdf
Ofcourse lot changed in 2 years but think KMK could continue pull on and in blue, wait seem worth but DYOR
Sill not sure what you are going on about. You seems to be reading some weird technical stuff with no relevance to Kromek. To make it simple for you, read about the wonderful technical breakthrough by Polarean and what it has done for its sp. Boffins + bright ideas does not = Sound share investment. Sorry it is not that simple or easy. Which is why Kromek sp is "in the gutter" and never likely to get out.
Just read this about a large US listed medical imaging solutions provider and Thier intention to focus on Photon counting imaging CT and the size of the addressable Asian markets....CZT based Photon counting tech...bodes well for Kmk I think.
Key takeaways from the earnings call include:
The Medical segment made up 75% of the annual revenues, driven significantly by the global CT market.
Varex's subsidiary, MeVis Medical Solutions, obtained FDA clearance for an AI-based software product, emphasizing the company's focus on photon counting technologies.
The Industrial segment announced the launch of XRpure, an irradiation system for decontaminating organic products, which is expected to add nearly $1 billion to the company's addressable market within five years.
Varex plans to invest in its Industrial segment and expand its use of photon counting technology in medical applications.
Varex Imaging (NASDAQ:VREX) Corporation reported strong fourth quarter and fiscal year 2023 earnings, with Q4 revenue reaching $227 million.
https://uk.investing.com/news/stock-market-news/earnings-call-varex-imaging-reports-solid-q4-2023-results-eyes-expansion-in-india-amid-chinas-challenges-93CH-3238576
Not sure what you are trying to say,but take a look at Polarean and their sp. Then do some research on what they have produced ,in technical terms .Leaves Kromek way behind and then look again at Polarean sp and its history.If you want a silly gamble there are better places to lose your money than Kromek.
"The day after seeing her Prenuvo results, Santarosa had a follow-up CT scan at a local hospital. The nodule was cancerous. She had it removed the following week.".....
"Lacy said Prenuvo's hardware was designed to do "almost as good a job" as contrast by using other techniques."
https://www.cnbc.com/2023/11/10/prenuvo-offers-2500-full-body-mri-scans-that-can-detect-cancer-early.html
@pedro.
You’ve gone quiet, pedro…….
Is everything ok? Or is it the sp trend line proving itself……
I was hoping it would rocket from here based on your blogs alone
A load of waffle.....
if all this was good then it would be hard to buy the shares. Instead, shareholders can't get rid of them quick enough!!!!!
wonder if mick33 has purchased any yet?
Look folks there are Aim companies out there who are miles ahead of Kromek with their technological breakthrough. As for kromek they have been boasting about their wonderful unique dynamic research breakthroughs for more than 5 years. Those claims had the sp at well above 30p. Look at the sp now, pathetic. Nearly everyone is wise to the Smoke and Mirrors. Given their big talk,yet again, there are no takers at more than 5p.. Ask yourselves why When investing, something looks too good to be true, it almost always is.
Super article, thx mike to share and also your comment about 'with assured CZT manufacturing capacity for future production sales', all seem bright as of yet, waiting game but worth
This is a fascinating article. The potential market value of CZT products is huge. I have always wondered why Kromek is not an M&A target for bigger players? Especially as the share price is so depressed against a proposed fair value. I appreciate there are three business models are play for Kromek, but the upside in this vertical is huge and the IP surely carries great value to bigger organisations. They could target Kromek for this IP, and then just spin out the other two business models if it so wanted. Anyone else thought about Kromek maybe being a target and why no one has moved on it?
If this funded development Breast imaging project come good
as it's looking increasingly likely it will, it's a company maker on its own I think.worth more than the present share price.
Low-Dose Molecular Breast Imaging (MBI) Could Improve Cancer Detection in Dense Breast Tissue.
https://www.medimaging.net/general-imaging/articles/294796139/low-dose-molecular-breast-imaging-mbi-could-improve-cancer-detection-in-dense-breast-
tissue.html#amp_tf=From%20%251%24s&aoh=16993944765823&referrer=https%3A%2F%2Fwww.google.com&share=https%3A%2F%2Fwww.medimaging.net%2Fgeneral-imaging%2Farticles%2F294796139%2Flow-dose-molecular-breast-imaging-mbi-could-improve-cancer-detection-in-dense-breast-tissue.html
All the recent medical imaging CZT contracts and design development deals have all mentioned the same phrase from memory...'with assured CZT manufacturing capacity for future production sales'
Sounds to me like Thier timing to ramp up CZT furnace capacity was well timed and a few more tier 2's might decide sooner than later to secure thier place on the growing preferential customers list..all good news to me.
Yet again great news stories here. The sp up one day and then back down. Just above 5p as i write. Seems few believe the latest "claims" of wonderful wealth making contracts. Wake up it is still just Smoke and Mirrors or there are numerous idiots failing to cash in as the sp will soon be 4x to-days price.
Plus -
On 31 October Kromek announced 3 more orders for CBRN detection worth a total of US$1.0m (£0.82m), most of which is expected to be recognised in the current year to 30 April 2024. Then on 7 November the Group announced a collaboration agreement with a new blue chip partner for CZT-based photon-counting CT medical applications; the partner provides solutions to over 100,000 customers globally.
Kromek had also announced the refinancing of its HSBC RCF in September and our outlook remains unchanged: indicative of a FY25 E EV/EBITDA multiple of 6.8x. As does our Fair Value at 26p / share.
Still in bombed out territory here sadly, and news on £££ for the latest CT medical deals with put a rocket under these I think...the deals are all stacking up nicely
Links a bit flakey for me
"Bio-detection becomes a commercial reality"
Recent new contracts show that Kromek’s investment in bio-hazard detection technology is becoming a commercial reality. On 26 October the Group received a US$5.9m (£4.84m) contract from the US Department of Homeland Security Countering Weapons of Mass Destruction (CWMD) Office - the first for Kromek - to research and develop technologies for agent-agnostic bio-detection.
After a strong run of encouraging news our positive outlook remains unchanged - as does Fair Value at 26p / share.
Read/hear new research note here (free access):
https://equitydevelopment.co.uk/research/bio-detection-becomes-a-commercial-reality
Yes, not know what kind of partnership contracts and model.
Any in public domain to research?
if long term,sticky and good financial terms, that will be good.
And not sure if KMK invests into them monetarily or just imparts technology and resources and what / when returns. Hope for good
Yeah. All good. Just seams strange that all the companies that KMk team up with seem to benefit more than kmk do.
Kromek teams up to use CZT technology to develop photon-counting CT scanners | AIM:KMK
https://www.proactiveinvestors.co.uk/companies/news/1032275/kromek-teams-up-to-use-czt-technology-to-develop-photon-counting-ct-scanners-1032275.html
Seems promising news, although collaboration partner not named, RNS mentions that "as the project is progressing towards commercialisation..", so looks safe to assume that perhaps none in short term but (hopefully) likely to fructify in the mid-term and fairly good potential, like to know who is this partner.
@ notsofastyou.
Most of us have been done with this share. Good luck
Nov 3rd - twitter kmk
"Over the past two days, we've had the pleasure of welcoming customers from Saudi Arabia to our HQ in County Durham."
Exchanging product and industry knowledge, as well as taking part in-depth product training; it's been a valuable visit for all.
a new customer by the look of it...